What's Happening?
Precision BioSciences will present clinical data from its ELIMINATE-B trial at the Hep-DART 2025 meeting in Honolulu, Hawaii. The trial investigates PBGENE-HBV, a gene editing therapy for chronic hepatitis
B, aiming to eliminate viral templates and provide potential cures. The presentation will feature safety and antiviral activity data across three cohorts, highlighting the therapy's promise in addressing the global burden of hepatitis B.
Why It's Important?
Chronic hepatitis B remains a significant health challenge, with millions affected worldwide. Precision BioSciences' gene editing approach offers a novel solution, potentially providing curative options where current therapies fall short. The presentation at Hep-DART 2025 allows the company to share its findings with the international hepatology community, fostering collaboration and advancing research in viral elimination. Success in this trial could lead to groundbreaking treatments, improving patient outcomes and reducing hepatitis B-related morbidity.
